What is Edwards Lifesciences's SG&A?

Edwards Lifesciences (EW) reported SG&A of $522.2M in Q1 2026.

How has Edwards Lifesciences's SG&A changed year-over-year?

Edwards Lifesciences's SG&A increased by 12.1% year-over-year, from $465.7M to $522.2M.

What is the long-term trend for Edwards Lifesciences's SG&A?

Over 4 years (2021 to 2025), Edwards Lifesciences's SG&A has grown at a 8.7% compound annual growth rate (CAGR), from $1.49B to $2.09B.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Edwards Lifesciences EW SG&A

SG&A at other companies

Cabot CorporationCBT

$67M+4.7%

UnifirstUNF

$157.41M+10.9%

BeldenBDC

$138.65M+5.4%

MYR GroupMYRG

$69.42M+11.0%

10x Genomics, Inc.TXG

$66.38M-26.0%

ADTADT

$364.77M-1.0%

Segments

By segment

See full

United States$154.1M+15.7%

Europe$71.8M-2.2%

Rest of World$48M+14.0%

Japan$15.9M-3.0%

Other financials

Income statement

See full

Revenue$1.6B+16.7%

Gross profit$1.3B+15.7%

Operating income$477.6M+21.0%

Net income$380.7M+6.3%

EPS (diluted)$0.66+8.2%

Balance sheet

See full

Cash & equivalents$2.4B-22.3%

Total debt$702.9M+0.5%

Total equity$10.3B+2.0%

Total assets$13.3B+2.3%

Cash flow

See full

Operating cash flow$43.8M-84.4%

CapEx$64.9M+15.9%

Free cash flow-$21.1M-109%

Valuation

See full

Market cap$51.66B+19.3%

Enterprise value$49.92B+22.2%

P/E47.1×+36.8×

P/S8.2×+0.4×

Profitability

See full

Gross margin77.9%-1.6pp

Operating margin21.4%-4.4pp

Net margin17.4%-58.3pp

FCF margin17.3%—

Returns & leverage

See full

Return on equity10.7%-37.8pp

Debt / equity0.1×0.0×

Current ratio4.4×0.0×

Where this comes from

Reported directly by Edwards Lifesciences in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Edwards Lifesciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edwards Lifesciences's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Edwards Lifesciences's SG&A?: Edwards Lifesciences (EW) reported SG&A of $522.2M in Q1 2026.
How has Edwards Lifesciences's SG&A changed year-over-year?: Edwards Lifesciences's SG&A increased by 12.1% year-over-year, from $465.7M to $522.2M.
What is the long-term trend for Edwards Lifesciences's SG&A?: Over 4 years (2021 to 2025), Edwards Lifesciences's SG&A has grown at a 8.7% compound annual growth rate (CAGR), from $1.49B to $2.09B.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.